

**Note to readers with disabilities:** *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to [508 standards](#) due to the complexity of the information being presented. If you need assistance accessing journal content, please contact [ehp508@niehs.nih.gov](mailto:ehp508@niehs.nih.gov). Our staff will work with you to assess and meet your accessibility needs within 3 working days.

### **Supplemental Material**

#### **Filaggrin Polymorphisms and the Uptake of Chemicals through the Skin – A Human Experimental Study**

Emelie Rietz Liljedahl, Gunnar Johanson, Helena Korres de Paula, Moosa Faniband, Eva Assarsson, Margareta Littorin, Malin Engfeldt, Carola Lidén, Anneli Julander, Karin Wahlberg, Christian Lindh, and Karin Broberg

#### **Table of Contents**

**Table S1.** Filaggrin null mutations with rs-id, and primer and probe pairs.

**Table S2.** The mode of ionization and transitions of the analyzed compounds and corresponding internal standards.

**Table S3.** Between-run and between-batch precision of the analytical methods determined at different concentrations.

**Table S4.** Area under the urine excretion rate curve ( $AUC_{(0-40h)}$ ), lag time for dermal absorption and dermal absorption rate constant by *FLG* genotype.

**Table S5.** Area under the urine excretion rate curve ( $AUC_{(0-40h)}$ ) adjusted for BMI and age, by *FLG* genotype.

**Table S6.** Area under the urine excretion rate curve ( $AUC_{(0-40h)}$ ), adjusted BMI and age, by *FLG* null and CNV genotype.

**Table S7.** Lag time for dermal absorption and dermal absorption rate constant by *FLG* null and CNV genotype. Analysis adjusted for BMI, age and sex.

**Table S8.** Volume of the central compartment, rate constant from the central compartment to the peripheral compartment, rate constant from the peripheral compartment to the central compartment, and excretion rate constant by *FLG* genotype.

**Table S9.** Volume of the central compartment, rate constant from the central compartment to the peripheral compartment, rate constant from the peripheral compartment to the central compartment, and excretion rate constant by *FLG* CNV genotype.

**Figure S1.** Residual plots for time point and excretion rate for pyrimethanil. Blue = *FLG* null, black = wt CNV20–22, green = wt CNV23–24.

**Figure S2.** Residual plots for time point and excretion rate for pyrene. Blue = *FLG* null, black = wt CNV20–22, green = wt CNV23–24.

**Figure S3.** Residual plots for time point and excretion rate for oxybenzone. Blue = *FLG* null, black = wt CNV 20–22, green = wt CNV 23–24.

**Figure S4.** The predicted vs observed values for excretion rates for pyrimethanil. Blue = *FLG* null, black = wt CNV 20–22, green = wt CNV 23–24.

**Figure S5.** The predicted vs observed values for excretion rates for pyrene. Blue = *FLG* null, black = wt CNV 20–22, green = wt CNV 23–24.

**Figure S6.** The predicted vs observed values for excretion rates for oxybenzone. Blue = *FLG* null, black = wt CNV 20–22, green = wt CNV 23–24.

**Figure S7.** Excretion curves for oxybenzone by *FLG* genotype. Each curve represents an individual. Excretion rates of a) *FLG* null (blue) carriers, b) wt carriers with CNV20–22 (black) and c) wt carriers with CNV23–24 (green).

**Figure S8.** Excretion curves for pyrene by *FLG* genotype. Each curve represents an individual. Excretion curves for a) *FLG* null (blue) , b) wt carriers with CNV20–22 (black) and c) wt carriers with CNV23–24 (green).

**Figure S9.** Examples of individual fits of the toxicokinetic model (purple line) to the excretion rate data (dots) for pyrimethanil. Blue = *FLG* null, black = wt CNV 20–22, green = wt CNV 23–24.